Neurocrine (NBIX) disclosed last night that in August, it received a civil investigative demand from the Department of Justice requesting certain documents and information related to its sales and marketing of Ingrezza. “We are cooperating with the DOJ’s request,” the company said in its quarterly filing. Shares of are down 5%, or $8.14, to $139.24 in morning trading.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $183 from $174 at Stifel
- Neurocrine price target raised to $160 from $156 at RBC Capital
- Neurocrine price target raised to $146 from $145 at Mizuho
- Neurocrine price target raised to $147 from $124 at BMO Capital
- Neurocrine price target raised to $179 from $175 at Piper Sandler